BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18181044)

  • 21. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
    Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
    Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression.
    De Feo E; Persiani R; La Greca A; Amore R; Arzani D; Rausei S; D'Ugo D; Magistrelli P; van Duijn CM; Ricciardi G; Boccia S
    Mutat Res; 2009 Apr; 675(1-2):60-5. PubMed ID: 19386249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
    Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
    Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma.
    Giuliani L; Jaxmar T; Casadio C; Gariglio M; Manna A; D'Antonio D; Syrjanen K; Favalli C; Ciotti M
    Lung Cancer; 2007 Sep; 57(3):273-81. PubMed ID: 17400331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.
    Kumari A; Bahl C; Singh N; Behera D; Sharma S
    Mol Biol Rep; 2016 Dec; 43(12):1383-1394. PubMed ID: 27614750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 codon 72 polymorphism and HPV status in lung cancer.
    Buyru N; Altinisik J; Isin M; Dalay N
    Med Sci Monit; 2008 Sep; 14(9):CR493-7. PubMed ID: 18758421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma.
    Denschlag D; Bettendorf H; Watermann D; Keck C; Tempfer C; Pietrowski D
    Fertil Steril; 2005 Jul; 84(1):162-6. PubMed ID: 16009172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphism of the p53 gene within the codon 72 in lung cancer patients.
    Biros E; Kalina I; Biros I; Kohut A; Bogyiová E; Salagovic J; Stubna J
    Neoplasma; 2001; 48(5):407-11. PubMed ID: 11845987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population.
    Hu Z; Miao X; Ma H; Wang X; Tan W; Wei Q; Lin D; Shen H
    Lung Cancer; 2005 Apr; 48(1):11-7. PubMed ID: 15777967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.
    Zhu ZZ; Liu B; Wang AZ; Jia HR; Jin XX; He XL; Hou LF; Zhu GS
    J Zhejiang Univ Sci B; 2008 Nov; 9(11):847-52. PubMed ID: 18988302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
    Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
    Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms--a case-control study in an Omani population.
    Al-Moundhri MS; Al-Nabhani M; Burney IA; Al-Farsi AA; Al-Bahrani B
    Mol Carcinog; 2009 Dec; 48(12):1170-6. PubMed ID: 19676106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population].
    Zhu ZZ; Cong WM; Liu SF; Dong H; Zhu GS; Wu MC
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(2):76-9. PubMed ID: 15774209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
    Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
    Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
    Wang AZ; Zhu ZZ; Cong WM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):168-71. PubMed ID: 18393238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
    Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela].
    Cañas M; Morán Y; Camargo ME; Rivero MB; Bohórquez A; Villegas V; Ramírez E; Rendón Y; Suárez A; Morales L; Useche E; Salazar S; Zambrano A; Ramírez A; Valderrama E; Briceño Z; Chiurillo MA
    Invest Clin; 2009 Jun; 50(2):153-61. PubMed ID: 19662811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.